Navigation Links
Studies suggest new brain protein may help in treating schizophrenia, insomnia and anxiety

A small protein in the brain that has only recently been discovered and, paradoxically, induces both profound wakefulness and a less anxious state, may represent a novel target for the treatment of psychotic behavior and schizophrenia, according to new research presented at the 6th International Congress of Neuroendocrinology (ICN 2006). ICN 2006 is being held at the David L. Lawrence Convention Center in Pittsburgh June 19 ?22.

Neuropeptide S (NPS), so named by Rainer K. Reinscheid, Ph.D., assistant professor, Program in Pharmaceutical Sciences, University of California, Irvine, is produced by a small cluster of cells in the brainstem, yet its specialized receptors are found in several areas of the brain, including those that are associated with the regulation of arousal, sleep and wakefulness, anxiety, appetite, learning and memory. Dr. Reinscheid and his colleagues reported finding the new neuropeptide just last year and described animal studies showing how binding of NPS to its receptors on the surfaces of neurons promotes strong arousal, suppresses all phases of sleep and lessens anxiety in stressful or unfamiliar situations.

Now, at ICN 2006, Dr. Reinscheid's group reports how NPS also can reduce the biochemical and behavioral symptoms of schizophrenia in an established animal model for this mental illness that affects some 2 million Americans. Animals pretreated with NPS before receiving a drug that normally induces psychotic-like behaviors did not develop the signature behavioral symptoms and neurochemical features of schizophrenia, reported Naoe Okamura, M.D., Ph.D., who is a co-worker of Dr. Reinscheid at the University of California, Irvine.

"Although preliminary, our animal studies indicate the NPS receptor should be explored as a target for the development of novel antipsychotic drugs. Whether molecules activating the NPS system will prove to be better drugs than others used to treat the symptoms of schizophrenia remains to be seen. We still have a very long way to go before proving it can alleviate symptoms in humans as we've seen it do in rodents," said Dr. Reinscheid.

"We've already seen how NPS is unique, being able to modulate both arousal and stress responses. So it could potentially be a target for drugs to treat anxiety and, interestingly, both insomnia and narcolepsy," he added.

The receptor for NPS belongs to a class of those with similar structure called G protein-coupled receptors. Collectively, they have a hand in modulating most every physiological process in the body and brain. Moreover, according to Dr. Reinscheid, about 40 percent of drugs on the market target the function and various actions of these receptors.

Dr. Reinscheid's lab is only beginning to understand how the NPS system works. Thus far, the team's research suggests it acts much like an excitatory neurotransmitter that initiates an impulse by the receiving neuron. Currently, the team is looking at whether natural mutations in the genes of NPS and its receptor might be associated with mental disorders and developing animal models that lack parts of the NPS system in order to better understand its functions.


'"/>

Source:University of Pittsburgh Medical Center


Related biology news :

1. Studies reveal methods viruses use to sidestep immune system
2. Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine
3. Studies clarify risk factors for mother-to-child transmission of hepatitis C virus
4. Studies on human genome variation provide insight into disease
5. Studies find general mechanism of cellular aging
6. Studies look at how genes affect antipsychotic drug response
7. Studies yield insight into the numerical brain
8. Studies force new view on biology of flavonoids
9. New studies suggest airborne SARS transmission is possible
10. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
11. Light therapy may combat fungal infections, new evidence suggests
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical research ... and document anonymization solution on October 4, 2017. Shadow is designed ... to comply with policy 0070 of the European Medicines Agency (EMA) ... ... Solutions ...
(Date:7/20/2017)... -- Delta (NYSE: DAL ) customers now can use fingerprints ... Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National ... Delta,s biometric boarding pass experience that launched ... into the boarding process to allow eligible Delta SkyMiles Members who are ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
Breaking Biology News(10 mins):
(Date:7/22/2018)... ... July 19, 2018 , ... The Center for Advancing Innovation ... by the Laura and John Arnold Foundation and MedImmune. The overarching goal of ... at 55 institutions, including the National Institutes of Health, the United States Army, ...
(Date:7/22/2018)... ... July 21, 2018 , ... Today the Weed Science Society ... off-target movement of dicamba herbicides is available on the Society’s website . The ... all stakeholders better understand and manage factors contributing to dicamba off-target movement. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... representations of a complex biological network, a depiction of a system of linkages ... said Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Lithuania, announced today that they have entered into a multiyear collaboration to identify ... CRISPR researchers with additional tools for gene editing across all applications. , Under ...
Breaking Biology Technology: